![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FMO3 |
Gene summary for FMO3 |
![]() |
Gene information | Species | Human | Gene symbol | FMO3 | Gene ID | 2328 |
Gene name | flavin containing dimethylaniline monoxygenase 3 | |
Gene Alias | FMOII | |
Cytomap | 1q24.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024R8Z4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2328 | FMO3 | P5T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.22e-01 | 0.1327 |
2328 | FMO3 | P12T-E | Human | Esophagus | ESCC | 3.97e-04 | 1.26e-01 | 0.1122 |
2328 | FMO3 | P40T-E | Human | Esophagus | ESCC | 2.18e-06 | 2.97e-01 | 0.109 |
2328 | FMO3 | P57T-E | Human | Esophagus | ESCC | 8.56e-12 | 5.06e-01 | 0.0926 |
2328 | FMO3 | P62T-E | Human | Esophagus | ESCC | 1.44e-17 | 6.48e-01 | 0.1302 |
2328 | FMO3 | P82T-E | Human | Esophagus | ESCC | 1.98e-12 | 1.51e+00 | 0.1072 |
2328 | FMO3 | P128T-E | Human | Esophagus | ESCC | 3.69e-73 | 4.06e+00 | 0.1241 |
2328 | FMO3 | NAFLD1 | Human | Liver | NAFLD | 1.30e-13 | 1.03e+00 | -0.04 |
2328 | FMO3 | HCC1_Meng | Human | Liver | HCC | 6.04e-14 | -2.22e-01 | 0.0246 |
2328 | FMO3 | HCC2_Meng | Human | Liver | HCC | 5.02e-08 | -2.53e-01 | 0.0107 |
2328 | FMO3 | HCC1 | Human | Liver | HCC | 2.31e-07 | 3.67e+00 | 0.5336 |
2328 | FMO3 | Pt13.b | Human | Liver | HCC | 2.46e-18 | 7.27e-02 | 0.0251 |
2328 | FMO3 | Pt14.b | Human | Liver | HCC | 1.31e-07 | 2.90e-01 | 0.018 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FMO3 | SNV | Missense_Mutation | novel | c.932N>T | p.Ala311Val | p.A311V | P31513 | protein_coding | tolerated(0.53) | benign(0.162) | TCGA-EY-A548-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FMO3 | deletion | Frame_Shift_Del | c.541delG | p.Val181TyrfsTer31 | p.V181Yfs*31 | P31513 | protein_coding | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
FMO3 | insertion | Frame_Shift_Ins | novel | c.471dupA | p.Glu158ArgfsTer10 | p.E158Rfs*10 | P31513 | protein_coding | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | ||
FMO3 | insertion | Frame_Shift_Ins | novel | c.12dupA | p.Val5SerfsTer28 | p.V5Sfs*28 | P31513 | protein_coding | TCGA-DD-AACT-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
FMO3 | deletion | In_Frame_Del | novel | c.1318_1320delTTC | p.Phe440del | p.F440del | P31513 | protein_coding | TCGA-DD-AADK-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
FMO3 | deletion | Frame_Shift_Del | novel | c.468delN | p.Glu158SerfsTer6 | p.E158Sfs*6 | P31513 | protein_coding | TCGA-DD-AADQ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
FMO3 | SNV | Missense_Mutation | novel | c.443N>T | p.Gly148Val | p.G148V | P31513 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
FMO3 | SNV | Missense_Mutation | c.985A>G | p.Thr329Ala | p.T329A | P31513 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-05-4426-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
FMO3 | SNV | Missense_Mutation | rs72549320 | c.94G>A | p.Glu32Lys | p.E32K | P31513 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-38-4625-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FMO3 | SNV | Missense_Mutation | c.1062N>C | p.Lys354Asn | p.K354N | P31513 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-55-1594-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2328 | FMO3 | ENZYME, DRUGGABLE GENOME | tacrolimus | TACROLIMUS | 28084894 | |
2328 | FMO3 | ENZYME, DRUGGABLE GENOME | nicotine | NICOTINE | 28290528 | |
2328 | FMO3 | ENZYME, DRUGGABLE GENOME | sulindac | SULINDAC | ||
2328 | FMO3 | ENZYME, DRUGGABLE GENOME | tamoxifen | TAMOXIFEN | 23962908 | |
2328 | FMO3 | ENZYME, DRUGGABLE GENOME | daunorubicin | DAUNORUBICIN | 25119182 | |
2328 | FMO3 | ENZYME, DRUGGABLE GENOME | rosuvastatin | ROSUVASTATIN | 20679960 | |
2328 | FMO3 | ENZYME, DRUGGABLE GENOME | itopride | ITOPRIDE | 25224784 | |
2328 | FMO3 | ENZYME, DRUGGABLE GENOME | anthracyclines and related substances | 23441093,21900104 | ||
2328 | FMO3 | ENZYME, DRUGGABLE GENOME | olanzapine | OLANZAPINE | 23147717 |
Page: 1 |